Bladder cancer

IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance

Retrieved on:

Sunday, January 7, 2024

Theta, Conference, HRD, Medicine, Neoplasm, IND, RECIST, Bladder cancer, Prostate cancer, SAN, GSK, J. P. Morgan, Prostate, Therapy, PSA

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates.

Key Points:

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 corporate guidance and program updates.
Presentation by Yujiro S. Hata, Chief Executive Officer followed by analyst-hosted Q&A with Anupam Rama, Managing Director, US SMID Biotechnology Equity Research, J.P. Morgan
IDEAYA's 2024 corporate guidance and program updates include:
Balance sheet of $511.1 million of cash, cash equivalents and marketable securities as of September 30, 2023, and $134.7 million estimated net proceeds from subsequent follow-on financing and $10 million receivable from GSK, is anticipated to fund operations into 2028
Preliminary IDE397 clinical efficacy observed in MTAP deletion solid tumors, including RECIST 1.1 complete response in bladder cancer patient, 33% tumor shrinkage in NSCLC patient by CT/PET, and multiple ctDNA molecular responses in NSCLC and bladder cancer
Preliminary IDE161 clinical efficacy observed in HRD solid tumors, including RECIST 1.1 partial responses in priority solid tumor types and >50% PSA reduction in a prostate cancer patient
Targeting ongoing enrollment of IDE161 Phase 1 expansion in HRD solid tumor priority types, including endometrial, colorectal, prostate, and ER+ HER2- breast cancers
Advancing Phase 1 dose escalation for GSK101 (IDE705) Pol Theta Helicase inhibitor, and targeting IND submission in 2024 for Werner Helicase Inhibitor Development Candidate ($7.0 million milestone upon IND clearance) under collaboration with GSK
Targeting multiple wholly-owned next generation development candidate nominations in 2024, including in MTAP-deletion, further advancing IDEAYA's multi-pronged strategy in MTAP-deletion and AI/ML and structurally-enabled drug discovery platform
IDEAYA's updated corporate presentation reflecting its 2024 corporate guidance is available on its website, at the Investor Relations page: https://ir.ideayabio.com/ .
A live audio webcast of the event, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at https://ir.ideayabio.com/events .
A replay of available webcasts will be accessible for 30 days following the live event.

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Retrieved on:

Thursday, January 4, 2024

IO, Merck Group, ASX, Autoimmune disease, Immune system, Death, Bladder cancer, Carcinoma, Hope, IMM, PD-L1, Avelumab, Research, Cancer, Transitional cell carcinoma, Patient, Safety, Transitional epithelium

SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.

Key Points:

The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha (“efti”) in combination with BAVENCIO® (avelumab) in up to 30 patients with metastatic urothelial carcinoma.
Encouragingly, responses were achieved even in cancer patients with low and negative PD-L1 expression, who typically would not be expected to respond to anti-PD-(L)1 therapy.
Daniel Pink, as part of the investigator-initiated INSIGHT platform for studies investigating efti in different combination treatments and routes of administration.
For 2023, it was estimated there would be 82,290 new cases of bladder cancer and 16,710 deaths in the US alone.1

CytomX Therapeutics Outlines 2024 Company Priorities and Milestones

Retrieved on:

Thursday, January 4, 2024

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.

Key Points:

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline.
“With INDs recently filed for wholly-owned programs, CX-2051 and CX-801, and continued progress in dose escalation with our Probody® T-Cell engager, CX-904, CytomX is well positioned as we enter 2024.
CytomX has a consistent track record of forming new strategic research and development alliances and achieving preclinical research and clinical milestones.
Cash runway is projected to the second half of 2025, excluding any potential milestones from existing collaborations or new business development.

Vesica Health to Present at the Seed Showcase, Part of Biotech Showcase, The Investor Conference for Innovators

Retrieved on:

Tuesday, January 2, 2024

Conference, Partnership, Bladder cancer, Health, Hematuria, Liquid biopsy, Showcase, HEALTH, Patient

IRVINE, Calif., Jan. 2, 2024 /PRNewswire/ -- VESICA HEALTH, INC., a multi-omics, liquid biopsy company transforming the management of hematuria patients and improving the early detection of bladder cancer, today announced that it has been selected to participate in the Seed Showcase, part of the 2024 Biotech Showcase™.

Key Points:

"We are delighted to share that Vesica Health was chosen to present in the Seed Showcase for investors at the annual Biotech Showcase in San Francisco," reported Christopher Thibodeau, CEO of Vesica Health.
"We are delighted that Vesica Health will be joining us in San Francisco and presenting at the Seed Showcase this year," said Sara Demy, CEO of Demy-Colton.
The conference takes place each year during one of the industry's largest gatherings and busiest weeks.
Registered attendees can attend Vesica Health's live presentation during the in-person event where CEO Christopher Thibodeau will share the company's investor presentation at the Seed Showcase.

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Retrieved on:

Tuesday, January 2, 2024

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.

Key Points:

ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million royalty financing and equity investment in the Company by Oberland Capital, with $210 million of gross proceeds received at closing on December 29, 2023.
The proceeds will also be used to fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors.
Oberland Capital has also an option to purchase an additional $10 million of common stock at a future date.
Jefferies LLC acted as exclusive financial advisor to the Company on the transaction.

Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program

Retrieved on:

Thursday, December 7, 2023

AIST, Medtech, Bladder cancer, Research, CMO, Vesica, Olympus Corporation, Standard of care, University, Business development, Cystoscopy, Diagnosis, Patient, Medical device

SINGAPORE, Dec 7, 2023 - (JCN Newswire) - Vesica AI, a promising medical startup company, has been selected as the winner of the inaugural Olympus Asia Pacific Innovation Program (OAIP).

Key Points:

SINGAPORE, Dec 7, 2023 - (JCN Newswire) - Vesica AI, a promising medical startup company, has been selected as the winner of the inaugural Olympus Asia Pacific Innovation Program (OAIP).
(From left) Olympus Corporation Asia Pacific CEO Marc Radatt, Vesica AI Co-founder, CMO, and CTO Atsushi Ikeda, Vesica AI CEO Albert Liu
Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, partnered with MedTech Innovator Asia Pacific, the industry's largest healthcare accelerator, to launch and facilitate the OAIP which ran throughout 2023.
As the winning innovator, Vesica AI will receive grant funding of $75,000 as well as an exclusive mentorship program with key thought leaders from Olympus.
They presented strongly, and through this process, we are delighted to have selected Vesica AI as the inaugural winner of the Olympus Asia Pacific Innovation program.

Intelligent Scopes and Mayo Clinic Collaborate to Develop AI Diagnostic Solutions in Urology for Improved Patient Outcomes

Retrieved on:

Thursday, December 21, 2023

Image, Urology, Bladder cancer, Research, Prognosis, Cystoscopy, Mayo Clinic, Times New Roman, Artificial intelligence, Cancer, Patient, Medical device

LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology.

Key Points:

LONDON and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Intelligent Scopes Corp, a subsidiary of Claritas HealthTech Ltd. is pleased to announce it has entered into a know-how agreement with Mayo Clinic to develop artificial intelligence (AI) solutions for surgical and endoscopic imaging in the field of urology.
Combining the research capabilities and clinical expertise of Mayo Clinic, with the technology of Intelligent Scopes in image enhancement and expertise in development of precision AI diagnostic tools, this collaboration aims to deliver software tools that aid urologists in the detection, surgery, and post-treatment surveillance.
This digital healthcare collaboration intends to deliver reliable AI diagnostic solutions that can be used by urologists globally for accurate detection of bladder cancer and to minimize unnecessary interventions thereby improving patient outcomes.
Early and accurate detection has the potential to significantly improve the prognosis for patients and reduce costs to providers and payors.

Notable Reports Predictive Precision Medicine Platform (PPMP) Accurately Predicted Fosciclopirox Trial Outcome

Retrieved on:

Monday, December 18, 2023

Patient, Risk, Drug development, Bladder cancer, Doctor of Philosophy, Ciclopirox, Cancer, Bias, Safety, AML, Pharmaceutical industry

FOSTER CITY, Calif. and KANSAS CITY, Mo., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (“Notable”) (Nasdaq: NTBL), a clinical-stage therapeutic platform company developing predictive precision medicines for cancer patients, and CicloMed, LLC (“CicloMed”), a developmental-stage pharmaceutical company focusing on unmet medical needs in oncology, today announced initial safety and efficacy data of fosciclopirox and the performance of PPMP, Notable’s Predictive Precision Medicines Platform, from the Phase 2a trial in adult patients with relapsed/refractory acute myeloid leukemia, R/R AML (NCT04956042). Fosciclopirox is sponsored by CicloMed and co-developed by both companies. In the Phase 2a trial, PPMP-predicted patient responses were confirmed by the actual responses to treatment.

Key Points:

In the Phase 2a trial, PPMP-predicted patient responses were confirmed by the actual responses to treatment.
“The successful outcome prediction means that Notable’s PPMP platform accomplished its goal in this trial,” stated Thomas Bock, M.D., Chief Executive Officer of Notable.
Eighteen heavily pre-treated patients were enrolled in the trial with nine patients evaluable for response assessment per-protocol.
Importantly, PPMP predicted that all patients enrolled into this trial would be non-responsive to fosciclopirox.

American Urological Association Names Next Education Chair

Retrieved on:

Thursday, December 14, 2023

Associate, Jackson Memorial Hospital, Bladder cancer, Urology, Learning, Fellow, Research, AUA, MBA, Prostate cancer, MD, Doctor of Philosophy, University, Emeritus, Management

Dr. Gonzalgo will assume the role of chair-elect on June 1, 2024, and begin his four-year term as chair on June 1, 2025.

Key Points:

Dr. Gonzalgo will assume the role of chair-elect on June 1, 2024, and begin his four-year term as chair on June 1, 2025.
Reporting to the Board of Directors, he will serve as the Chair of the Education Council overseeing nine different committees and work groups and coordinating activities with the Secretary and Associate Secretaries for AUA's International Education Plan.
"We are looking forward to working with Dr. Gonzalgo in his new role as chair of our Office of Education," said Dr. Randall Meacham, AUA President.
“We have a tremendous opportunity to shape the future of urological education with the highest standards of learning across all areas of urology.

Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01

Retrieved on:

Wednesday, December 6, 2023

RNA, Bladder cancer, Therapy, Clinical trial, Pharmacokinetics, BCG, SaRNA, RNAa, Patient, Safety, NMIBC, Pharmaceutical industry

JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.

Key Points:

JIANGSU, China, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a leader in the field of small activating RNA (saRNA) therapeutics, is excited to announce the submission of a clinical trial application in Australia.
This milestone marks Ractigen's transition into clinical development, with RAG-01 targeting NMIBC.
RAG-01 is recognized as the second saRNA drug worldwide to enter clinical trials and the first of its kind in China to achieve this critical milestone.
This development signifies a remarkable advancement in RNA-based therapeutic applications, especially in the context of challenging cancer treatments.